Form 4: ADMA Biologics CFO Reports Routine Stock Holdings Update Following RSU Vesting

ADMA Biologics' CFO and Treasurer, Brad L. Tade, reported a change in beneficial ownership, with 9,838 shares withheld for tax purposes upon the vesting of restricted stock units, leaving a total beneficial ownership of 246,542 shares.

Summary

• Brad L. Tade, the Chief Financial Officer and Treasurer of ADMA Biologics, Inc. (ADMA), reported a change in his beneficial ownership.
• On June 26, 2025, 9,838 shares were withheld by ADMA Biologics to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units (RSUs). This was not an open market sale of securities.
• The shares withheld for tax purposes were valued at $18.4 per share.
• Following this transaction, Brad L. Tade beneficially owns a total of 246,542 shares.
• The beneficial ownership includes 62,227 unvested RSUs granted on February 19, 2025, vesting quarterly over four years.
• It also includes 72,400 unvested RSUs granted on July 24, 2024, vesting quarterly over four years.
• Additionally, 37,500 unvested RSUs granted on February 26, 2024, vesting quarterly over four years, are included.
• Furthermore, 50,000 unvested RSUs granted on June 26, 2023, vesting quarterly over four years, are part of the beneficial ownership.
• The total beneficial ownership also comprises 24,415 shares acquired through open market purchases and the vesting of RSUs after tax withholding.

Sentiment

Score: 7

Explanation: The filing indicates a routine executive compensation event (RSU vesting) and subsequent tax withholding, which is a neutral to positive sign as it reflects ongoing executive compensation and continued significant beneficial ownership by a key officer, aligning their interests with shareholders.

Positives

• The vesting of restricted stock units indicates a routine compensation event for the CFO, which helps align management's interests with shareholder value.
• Brad L. Tade retains a substantial beneficial ownership of 246,542 shares, demonstrating continued commitment to the company.

Negatives

• 9,838 shares were withheld by the Issuer to cover mandatory tax obligations, which reduces the direct share count of the reporting person.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The transaction involves the vesting of restricted stock units (RSUs) granted by ADMA Biologics, Inc. to its CFO and Treasurer, Brad L. Tade, which is a standard compensation arrangement between the company and an executive.

Stakeholder Impact

• Shareholders: The continued significant beneficial ownership by the CFO aligns management's interests with shareholder value.
• Employees: The RSU vesting is part of executive compensation, reflecting standard employee incentive programs.

Key Dates

Recommendation

Keywords

ADMA Biologics, ADMA, Form 4, SEC filing, insider transaction, beneficial ownership, restricted stock units, RSU, stock withholding, CFO, corporate governance